Icon

Fosamax - (70 mg/ 75 ml; Oral solution)

Alendronate Sodium Merck
70 mg/ 75 ml; Oral solution
Less Than $1000 mn
Less Than 5
None
None None
Less Than 5
Less Than 5
Treatment and prevention of osteoporosis
Yes
** ******* *** ******* ** **** ******* *********. **** ***** *** ******** ***** ******** *** ******** *** ******* ** *** ****.
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*****
  1. *** *, **** : * **** ** ** ***** *** ******* ** ******* *** *******.
  2. *** **, **** : ***** ******** ***** ******** *** ******** *** *******

Fosamax - (5, 10, 35, 40, 70 mg; Tablet, Oral)

Alendronate Sodium Merck
5, 10, 35, 40, 70 mg; Tablet, Oral
Less Than $1000 mn
None
Less Than 5
None None
More Than 5
Less Than 5
Treatment and prevention of osteoporosis
Yes
Fosamax Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9
**** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* ******* *** ********* *** *********
******** ******* ******* ******* ******* ******* ******* ******* ******* *******
****** ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** ***/*** *** *,**** ******* ******** ************ *********
******** **\** *** *,**** ******* ******** *** ****** *** ****
****** **\** *** *,**** ******* ******** *** ****** *** ****
  1. *** *, **** : ***** ***** * **** ******* **** ** *** ** ** ******** **** *** **** ****** **** ****** '*** ( **** *** ****)
  2. *** **, **** : ********* ** ****** ** *****, **** ******* ** **
  3. *** **, **** : ********** ********* **** ****
  4. *** *, **** : ***** ***** ***** ******* ******** (******) ** *** ** ** ******** *** **** ****** **** ******* ’*** (**** *, ****), ’*** (**** *, ****), ’*** (******** *, ****), ’*** (******** *, ****), ’*** (**** *, ****), ’*** (**** *, ****), ’***(******* **, ****), ’*** (******* **, ****), *** ’*** (******* **, ****) ********* *, **, **, ***, ** ** **** *******
  5. *** *, **** : ********** **** ******** ** ********* **** ********* *** **** ** ******* ****** ************
  6. *** **, **** : ****** ******** ***** ***** *** **** ** ****** **** ******* ’*** (**** *, ****), ’*** (**** *, ****), ’*** (******** *, ****), ’*** (******** *, ****), ’*** (**** *, ****), ’*** (**** *, ****), ’***(******* **, ****), ’*** (******* **, ****), *** ’*** (******* **, ****) *** *, **, **, ** ** *******
  7. *** *, **** : ***** ***** * **** ******* ****** ** ** ** ********
  8. *** **, **** : ********** **** ****** ** *********, ****** ******** ** *** ****** ** **
  9. *** *, **** : ** ** ********'* ********* ** ******** ** ****, ******* ** **** *** ******** ** **

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.